| TA135 |
Mesothelioma - pemetrexed disodium (TA135) |
|
-
-
Pemetrexed disodium for the treatment of mesothelioma
Pemetrexed is recommended as a possible treatment for malignant pleural mesothelioma in people:
- with advanced disease
- whose cancer is not suitable for surgical resection (removal) and
- who have a World Health Organization (WHO) performance status of 0 (able to carry out all normal activity without restriction) or 1 (restricted in strenuous activity but able to move around and carry out light work).
Healthcare professionals should not stop prescribing pemetrexed for people who were already taking it when the guidance was issued. These patients should be able to carry on taking pemetrexed until they and their specialist decide that it is the right time to stop treatment.
-
Other information
How this guidance was produced
Background information
This page was last updated: 12 December 2011
-
Guidance formats
-
Implementation tools and resources
See this guidance in practice
Patient
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
NICE Guidance
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
Full Guidance
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.
